Project Details
Description
INCLISIRAN A PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED TRIAL TO EVALUATE THE EFFECT OF 300 MG OF INCLISIRAN SODIUM GIVEN AS SUBCUTANEOUS INJECTIONS IN SUBJECTS WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE (ASCVD) AND ELEVATED LOW-DENSITY LIPOPROTEIN
| Status | Finished |
|---|---|
| Effective start/end date | 11/1/17 → 3/30/18 |
Funding
- THE MEDICINES COMPANY
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.